Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises

Core Insights - Amarin Corporation (AMRN) reported a narrower loss of $0.03 per share for Q2 2025, compared to the Zacks Consensus Estimate of a loss of $0.66 per share, and break-even earnings in the same quarter last year [1][7] - Total revenues for Q2 2025 were $72.7 million, exceeding the Zacks Consensus Estimate of $46 million, and representing an 8% increase from the previous year, driven by higher licensing and royalty revenues [2][7] Financial Performance - Adjusted earnings, excluding stock-based compensation, licensing fees, and restructuring expenses, were $0.04 per share, up from $0.01 per share in the year-ago quarter [2] - Net product revenues from Vascepa, the company's sole marketed drug, were $46.6 million, a 2% decline year-over-year, with U.S. product revenues down 17% to $36.5 million due to increased generic competition [4][8] - Licensing and royalty revenues increased by 31% year-over-year to $26.1 million, attributed to an upfront payment from a European licensing agreement and higher royalties [8] Market Reaction - Shares of Amarin rose by 2.2% on July 30 following the better-than-expected results, with the stock up 54.3% year-to-date compared to a 1% rise in the industry [3] Strategic Developments - In June 2025, Amarin signed a long-term exclusive licensing agreement with Recordati to commercialize Vazkepa in 59 European countries, receiving an upfront payment of $25 million and potential milestone payments of up to $150 million [10][11] - A global restructuring initiative is expected to save approximately $70 million over the next 12 months, which is anticipated to enhance European growth [7][11] Cash Position - As of the end of Q2 2025, Amarin had cash and investments totaling $298.7 million, an increase from $281.8 million as of March 31, 2025 [9]